+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gatifloxacin Market - Global Forecast 2026-2032- Product Image
Gatifloxacin Market - Global Forecast 2026-2032- Product Image
New

Gatifloxacin Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 194 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5967939
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gatifloxacin market is undergoing notable transformation, shaped by evolving clinical priorities, regulatory policies, and supply chain considerations. Senior leaders evaluating portfolio strategies must navigate increasing scrutiny, stewardship imperatives, and global trade disruptions, making clear visibility into this specialty market vital.

Market Snapshot: Gatifloxacin Market Performance and Direction

The gatifloxacin market grew from USD 348.23 million in 2025 to USD 366.22 million in 2026, with a projected CAGR of 4.97% that will see it reach USD 489.26 million by 2032. This upward trend is driven by the demand for targeted therapies, ongoing innovation in ophthalmic and parenteral formulations, and dynamic shifts in global pharmaceutical trade and regulation.

Scope & Segmentation

  • Product Types: Injectable (200 mg, 400 mg), ophthalmic drops (0.3%), oral tablets (200 mg, 400 mg)
  • Therapeutic Applications: Ocular infections, dermal infections, respiratory tract infections, urinary tract infections
  • Administration Routes: Ophthalmic, oral, parenteral
  • Distribution Channels: Hospital pharmacy (public, private), retail pharmacy (chain, independent), online pharmacy
  • Geographies: Americas; Europe, Middle East & Africa; Asia-Pacific
  • Technology & Formulation Innovation: Advances in delivery systems, preservative choices, formulation stability, and patient adherence accessibility

Segment Relevance and Regional Dynamics

Each segment presents unique clinical and procurement drivers. Ophthalmic drops address stewardship imperatives through localized therapy, while injectables require precise sterility and distribution. Regional variation in regulation, local manufacturing, and distribution access further define strategy—from the Americas’ established tendering to Asia-Pacific’s manufacturing leadership.

Key Takeaways for Decision-Makers

  • Antibiotic stewardship and resistance management increasingly guide prescriber and purchaser decisions, advancing the shift toward topical and localized gatifloxacin applications.
  • Formulation innovation enhances product differentiation and patient adherence while addressing prior concerns regarding systemic use safety.
  • Procurement strategies now emphasize supply chain resilience, with investment in diversified sourcing and contingency planning seen as essential for consistent product access.
  • Regulatory scrutiny, including enhanced post-market safety monitoring, elevates the value of proactive engagement with authorities and robust pharmacovigilance planning.
  • Distribution channel optimization—aligning with institutional, retail, and online procurement patterns—allows for tailored market access and minimized supply disruptions.
  • Strategic partnerships with contract manufacturers and dedicated API suppliers are central to operational resilience, especially during industry-wide shocks.

Tariff Impact on Supply Chain Continuity

United States tariffs imposed in 2025 introduced new challenges to the gatifloxacin market. Tariffs increased costs in sourcing active ingredients, reconfigured supply chain networks, and compelled both manufacturers and buyers to reconsider production localization. The result is extended lead times, higher inventory buffers, and greater scrutiny of supplier diversification strategies. These dynamics may affect timely patient access, particularly in segments where therapeutic substitutes are limited.

Methodology & Data Sources: Gatifloxacin Market

This analysis synthesizes insights from primary interviews with clinicians, procurement experts, regulatory professionals, and CMOs, as well as secondary sources including clinical literature, product documentation, and market data. Triangulation and expert validation ensure findings are grounded in real-world decision criteria and operational detail.

Why This Report Matters

  • Aligns product and procurement strategy with shifting regulatory, clinical, and market realities, equipping leaders for informed resource allocation.
  • Offers an actionable framework for supply chain resilience and formulation innovation, tailored to regional and segment-specific priorities.
  • Enables data-driven engagement with stakeholders across regulatory, clinical, and sourcing functions, anchoring critical commercial and operational decisions.

Conclusion

Future success in the gatifloxacin market depends on targeted formulation, adaptive supply chain strategies, and responsive stakeholder engagement. Decision-makers equipped with comprehensive, accurate insights are well positioned to navigate ongoing clinical and regulatory shifts while ensuring continued market access and product value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Gatifloxacin Market, by Product Type
8.1. Injectable
8.1.1. 200 Mg
8.1.2. 400 Mg
8.2. Ophthalmic Drops
8.3. Oral Tablets
8.3.1. 200 Mg
8.3.2. 400 Mg
9. Gatifloxacin Market, by Route Of Administration
9.1. Ophthalmic
9.2. Oral
9.3. Parenteral
10. Gatifloxacin Market, by Application
10.1. Dermal Infections
10.2. Ocular Infections
10.3. Respiratory Tract Infections
10.4. Urinary Tract Infections
11. Gatifloxacin Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Gatifloxacin Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Gatifloxacin Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Gatifloxacin Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Gatifloxacin Market
16. China Gatifloxacin Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Abbott Laboratories
17.6. Adore Pharmaceuticals Pvt. Ltd.
17.7. Allergan, Inc.
17.8. Apotex Inc.
17.9. Bristol-Myers Squibb Company
17.10. Cipla Ltd.
17.11. Dr. Reddy's Laboratories Ltd.
17.12. Knox Life Sciences
17.13. Lupin Pharmaceuticals, Inc.
17.14. Mylan N.V.
17.15. Novartis AG
17.16. Roche Holding AG
17.17. Sandoz International GmbH
List of Figures
FIGURE 1. GLOBAL GATIFLOXACIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GATIFLOXACIN MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GATIFLOXACIN MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GATIFLOXACIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GATIFLOXACIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES GATIFLOXACIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA GATIFLOXACIN MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GATIFLOXACIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GATIFLOXACIN MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GATIFLOXACIN MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GATIFLOXACIN MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GATIFLOXACIN MARKET SIZE, BY 200 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GATIFLOXACIN MARKET SIZE, BY 200 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GATIFLOXACIN MARKET SIZE, BY 200 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GATIFLOXACIN MARKET SIZE, BY 400 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GATIFLOXACIN MARKET SIZE, BY 400 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GATIFLOXACIN MARKET SIZE, BY 400 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GATIFLOXACIN MARKET SIZE, BY OPHTHALMIC DROPS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GATIFLOXACIN MARKET SIZE, BY OPHTHALMIC DROPS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GATIFLOXACIN MARKET SIZE, BY OPHTHALMIC DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GATIFLOXACIN MARKET SIZE, BY 200 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GATIFLOXACIN MARKET SIZE, BY 200 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GATIFLOXACIN MARKET SIZE, BY 200 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GATIFLOXACIN MARKET SIZE, BY 400 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GATIFLOXACIN MARKET SIZE, BY 400 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GATIFLOXACIN MARKET SIZE, BY 400 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GATIFLOXACIN MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GATIFLOXACIN MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GATIFLOXACIN MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GATIFLOXACIN MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GATIFLOXACIN MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GATIFLOXACIN MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GATIFLOXACIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GATIFLOXACIN MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GATIFLOXACIN MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GATIFLOXACIN MARKET SIZE, BY DERMAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GATIFLOXACIN MARKET SIZE, BY DERMAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GATIFLOXACIN MARKET SIZE, BY DERMAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GATIFLOXACIN MARKET SIZE, BY OCULAR INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GATIFLOXACIN MARKET SIZE, BY OCULAR INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GATIFLOXACIN MARKET SIZE, BY OCULAR INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GATIFLOXACIN MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GATIFLOXACIN MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GATIFLOXACIN MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GATIFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GATIFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GATIFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GATIFLOXACIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GATIFLOXACIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GATIFLOXACIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GATIFLOXACIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GATIFLOXACIN MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GATIFLOXACIN MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GATIFLOXACIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GATIFLOXACIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GATIFLOXACIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GATIFLOXACIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS GATIFLOXACIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 61. AMERICAS GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 62. AMERICAS GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 63. AMERICAS GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 64. AMERICAS GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 65. AMERICAS GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. NORTH AMERICA GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 69. NORTH AMERICA GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 71. NORTH AMERICA GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. LATIN AMERICA GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 76. LATIN AMERICA GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 77. LATIN AMERICA GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 78. LATIN AMERICA GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 79. LATIN AMERICA GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA GATIFLOXACIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. EUROPE GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. EUROPE GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 90. EUROPE GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 91. EUROPE GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 92. EUROPE GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93. EUROPE GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 94. EUROPE GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 97. MIDDLE EAST GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102. AFRICA GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. AFRICA GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 104. AFRICA GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 105. AFRICA GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 106. AFRICA GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 107. AFRICA GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 108. AFRICA GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL GATIFLOXACIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. ASEAN GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. ASEAN GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 119. ASEAN GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 120. ASEAN GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 121. ASEAN GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 122. ASEAN GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 123. ASEAN GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124. GCC GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GCC GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 126. GCC GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 127. GCC GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 128. GCC GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 129. GCC GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 130. GCC GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. BRICS GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. BRICS GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 140. BRICS GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 141. BRICS GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 142. BRICS GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. BRICS GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 144. BRICS GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. G7 GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. G7 GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 147. G7 GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 148. G7 GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 149. G7 GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 150. G7 GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 151. G7 GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. NATO GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. NATO GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 154. NATO GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 155. NATO GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 156. NATO GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. NATO GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 158. NATO GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL GATIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES GATIFLOXACIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 162. UNITED STATES GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 164. UNITED STATES GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. UNITED STATES GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. CHINA GATIFLOXACIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 168. CHINA GATIFLOXACIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 169. CHINA GATIFLOXACIN MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 170. CHINA GATIFLOXACIN MARKET SIZE, BY ORAL TABLETS, 2018-2032 (USD MILLION)
TABLE 171. CHINA GATIFLOXACIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. CHINA GATIFLOXACIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 173. CHINA GATIFLOXACIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Gatifloxacin market report include:
  • Abbott Laboratories
  • Adore Pharmaceuticals Pvt. Ltd.
  • Allergan, Inc.
  • Apotex Inc.
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Knox Life Sciences
  • Lupin Pharmaceuticals, Inc.
  • Mylan N.V.
  • Novartis AG
  • Roche Holding AG
  • Sandoz International GmbH

Table Information

Report AttributeDetails
No. of Pages194
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 366.22 Million
Forecasted Market Value ( USD ) by 2032 $ 489.26 Million
Compound Annual Growth Rate4.9%
Regions CoveredGlobal
No. of Companies Mentioned14

Related Topics

Related Reports

Gatifloxacin (CAS 112811-59-3) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Gatifloxacin (CAS 112811-59-3) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Levofloxacin Hemihydrate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Levofloxacin Hemihydrate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
India Ciprofloxacin Market, By Region, Competition, Forecast and Opportunities, 2021-2031F - Product Image

India Ciprofloxacin Market, By Region, Competition, Forecast and Opportunities, 2021-2031F

  • Report
  • 70 Pages
  • India
From
Sulfamethoxazole Sulfadiazine & Trimethoprim Tablets Market - Global Forecast 2025-2030 - Product Image

Sulfamethoxazole Sulfadiazine & Trimethoprim Tablets Market - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Balofloxacin Market - Global Forecast 2026-2032 - Product Image

Balofloxacin Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From

About the Gatifloxacin Market

Gatifloxacin is an antibiotic used to treat a variety of bacterial infections. It belongs to the class of drugs known as fluoroquinolones, which work by inhibiting the growth of bacteria. Gatifloxacin is used to treat respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other bacterial infections. It is also used to treat certain sexually transmitted diseases. Gatifloxacin is available in both oral and intravenous forms. Gatifloxacin is generally well tolerated, but it can cause side effects such as nausea, vomiting, diarrhea, and headache. It can also cause serious side effects such as tendon rupture, liver damage, and increased risk of tendinitis and tendon rupture. Gatifloxacin is available in generic form and is also sold under the brand names Tequin, Gatiflo, and Zagam. It is manufactured by several pharmaceutical companies, including GlaxoSmithKline, Merck, and Pfizer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.